Global Encephalitis Vaccines Market Size (2024 - 2029)

The Encephalitis Vaccines market is anticipated to experience notable growth over the forecast period, driven by the increasing demand for immunization due to the high mortality and morbidity rates associated with encephalitis. The market's expansion is further supported by government initiatives promoting vaccination programs and strategic actions by key players, such as product launches and mergers. Although the market faced initial setbacks during the COVID-19 pandemic, it regained momentum as vaccination efforts resumed. Despite these positive trends, concerns regarding vaccine side effects and other challenges may hinder market growth.

Market Size of Global Encephalitis Vaccines Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Encephalitis Vaccines Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 5.20 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration Low

Major Players

Encephalitis Vaccines Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Encephalitis Vaccines Market Analysis

The Encephalitis Vaccines market is projected to grow with a CAGR of 5.2% over the forecast period.

The COVID-19 pandemic had a substantial influence on the market studied in the early months of the pandemic because people were unable to acquire planned vaccinations due to lockdowns and restrictions on non-emergency hospital visits. However, once the COVID-19 epidemic was under control in 2021, immunizations resumed, allowing the industry to regain its momentum. Several studies revealed that COVID-19 vaccination caused few occurrences of encephalitis. According to the study published in February 2022, titled "Acute encephalitis after COVID-19 vaccination: A case report and literature review" due to the current global pandemic, vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) have been distributed worldwide; nonetheless, incidences of SARS-CoV-2 vaccination-related encephalitis have been documented infrequently. Thus, due to increasing incidence of encephalitis after COVID-19 vaccination significantly impacted the market.

The major factor attributing to the growth of the market is the high mortality and morbidity rate caused due to the incidence of encephalitis virus. Furthermore, increasing government initiatives for vaccination programs is boosting the market. For instance, according to the World Health Organization as of April 28, 2022, 37 human cases of Japanese encephalitis (25 laboratory-confirmed cases and 12 probable cases) had been documented in four Australian states. Moreover, according to the study titled "Global magnitude of encephalitis burden and its evolving pattern over the past 30 years" published in June 2022, there were 1,444,720 incident cases, 89,900 fatalities, and 4.80 million DALYs associated with encephalitis worldwide in 2019. As the number of cases and fatalities rises, individuals must take preventive measures such as immunisation, which increases demand for encephalitis vaccines, thereby boosting the market growth.

Additionally, various strategies adopted by the key market players such as product launches, mergers, and acquisitions are likely to boost the market growth. For instance, in August 2021, Pfizer Inc. revealed that the TICOVAC (tick-borne encephalitis (TBE) vaccine) was approved by the United States Food and Drug Administration (FDA) for active immunization to prevent TBE in individuals 1 year of age and older. TICOVAC is the one of the first FDA-approved vaccine to help protect United States adults and children against the TBE virus when visiting or living in TBE endemic areas.

Thus, owing to the abovementioned factors, the market is expected to project significant growth over the forecast period. However, the side effects of the vaccine and the challenges of the vaccine constrain market growth.

Encephalitis Vaccines Industry Segmentation

As per the scope of the report, encephalitis is inflammation of the brain. There are several causes, but the most common is a viral infection. Encephalitis can also cause confused thinking, seizures, or problems with senses or movement. The Encephalitis Vaccines Market is segmented by Vaccine Type (Mouse Brain-Derived Inactivated Vaccine, Cell Culture-Derived Inactivated Vaccine, Cell Culture-Derived Live Attenuated Vaccine), Indication Type (Japanese Encephalitis, Tick-Borne Encephalitis, Rabies Encephalitis), End-User (Child, and Adult), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Vaccine Type
Mouse Brain-Derived, Inactivated Vaccine
Cell Culture-Derived, Inactivated Vaccine
Cell Culture-Derived, Live Attenuated Vaccine
By Type Of Indication
Japanese Encephalitis
Tick-Borne Encephalitis
Rabies Encephalitis
By End-User
Child
Adult
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Encephalitis Vaccines Market Size Summary

The encephalitis vaccines market is poised for significant growth, driven by the high mortality and morbidity rates associated with encephalitis viruses and increased government initiatives for vaccination programs. The market experienced a temporary setback during the COVID-19 pandemic due to lockdowns and restrictions, but it regained momentum as immunizations resumed. The pandemic also highlighted the need for encephalitis vaccines, as rare cases of encephalitis were reported following COVID-19 vaccinations. Key market players are actively engaging in strategies such as product launches, mergers, and acquisitions to enhance their market presence. The introduction of vaccines like TICOVAC in the United States underscores the ongoing efforts to combat encephalitis in endemic areas, further propelling market growth.

The Japanese Encephalitis (JE) vaccine segment is expected to witness robust growth, particularly in Asia, where the disease is endemic. The increasing incidence of JE and government-led vaccination initiatives, such as mass immunization drives in countries like India, are significant contributors to this growth. Organizations like WHO, UNICEF, and Gavi are playing a crucial role in promoting vaccination to prevent the spread of JE. The market is also benefiting from investments in research and development, the entry of new manufacturers, and the rise of medical tourism in the region. The competitive landscape is characterized by major players like Valneva SE, Bharat Biotech, and Pfizer Inc., who are focusing on expanding their vaccine offerings and enhancing manufacturing capabilities to meet the growing demand.

Explore More

Global Encephalitis Vaccines Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 High Mortality and Morbidity Rate Caused Due to the Incidence of Encephalitis Virus

      2. 1.2.2 Rise in Government Initiatives for Vaccination Programs

    3. 1.3 Market Restraints

      1. 1.3.1 Side Effects and Challenges With the Vaccines

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Vaccine Type

      1. 2.1.1 Mouse Brain-Derived, Inactivated Vaccine

      2. 2.1.2 Cell Culture-Derived, Inactivated Vaccine

      3. 2.1.3 Cell Culture-Derived, Live Attenuated Vaccine

    2. 2.2 By Type Of Indication

      1. 2.2.1 Japanese Encephalitis

      2. 2.2.2 Tick-Borne Encephalitis

      3. 2.2.3 Rabies Encephalitis

    3. 2.3 By End-User

      1. 2.3.1 Child

      2. 2.3.2 Adult

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Global Encephalitis Vaccines Market Size FAQs

The Global Encephalitis Vaccines Market is projected to register a CAGR of 5.20% during the forecast period (2024-2029)

Valneva SE., Bharat Biotech, BIKEN, Pfizer Inc. and GlaxoSmithKline are the major companies operating in the Global Encephalitis Vaccines Market.

Encephalitis Vaccines Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)